Repurposed Tocilizumab in Patients with Severe COVID-19

The coronavirus disease 2019 (COVID-19) has caused a global pandemic, resulting in considerable morbidity and mortality. Tocilizumab, an inhibitor of IL-6, has been widely repurposed as a treatment of severely ill patients without robust evidence supporting its use. In this study, we aimed to system...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Immunol
Autori principali: Tian, Jianbo, Zhang, Ming, Jin, Meng, Zhang, Fengqin, Chu, Qian, Wang, Xiaoyang, Chen, Can, Yue, Huihui, Zhang, Li, Du, Ronghui, Zhao, Dong, Zeng, Zhaofu, Zhao, Yang, Liu, Kui, Wang, Mengmei, Hu, Ke, Miao, Xiaoping, Zhang, Huilan
Natura: Artigo
Lingua:Inglês
Pubblicazione: AAI 2021
Soggetti:
Infectious Disease and Host Response
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7812057/
https://ncbi.nlm.nih.gov/pubmed/33298617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.2000981
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi